Although it remains a controversial issue in oncology practice and should be interpreted with caution, on a case by case basis, in correlation with stage, degree of differentiation and MSI status, CEA is a useful prognostic biomarker in CRC, due to its validated clinical applicability, wide availability and cost effectiveness. This evidence concerns the gene CEACAM5 and colorectal carcinoma.